Compare Amphastar Pharmaceuticals Inc (AMPH) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Monster Beverage Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Monster Beverage Corp trades at $45.6 (market cap $89.56B). The key difference: Monster Beverage Corp is far larger — about 103.7× Amphastar Pharmaceuticals Inc's market cap, and Monster Beverage Corp is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | MNST | |
|---|---|---|
Market Cap | $863.95M | $89.56B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $49.97 |
52-Week Low | $16.87 | $30.86 |
Enterprise Value | $1.26B | $87.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Monster Beverage (MNST) trades at $45.18, down 4.04% in the last 24 hours, with a bearish technical signal. The company reported strong Q2 2026 earnings, beating estimates with $0.60 EPS and record sales of $2.54 billion, driven by international growth. Financials show robust revenue growth from $8.29 billion in 2025 to a projected $9.2 billion in 2026, with net income margins above 23%. A 2-for-1 stock split is scheduled for August 11, 2026.
Outlook remains positive due to consistent earnings beats and global expansion, but high valuation ratios like a P/E of 41.83 pose risks. Analyst consensus is bullish with a $51.14 price target, though competition and economic sensitivity could pressure margins. Investors should weigh growth potential against premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
